Bibliography
- JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim . Biophys. Acta (1976) 455:152–162.
- •The first paper identifying a membrane-bound protein as being responsible for drug resistance.
- AMBUDKAR SV, KIMCHI-SARFATY C, SAUNA ZE, GOTTESMAN MM: P-glycoprotein: from genomics to mechanism . Oncogene (2003) 22:7468–7485.
- ••A recent review highlighting the progressin understanding the structure and function of P-gp.
- RADERER M, SCHEITHAUER W: Clinical trials of agents that reverse multi-drug resistance. A literature review. Cancer (1993) 73:3553–3563.
- •A study demonstrating that the use of modulators of the first generation give rise to serious side effects.
- RAMACHANDRAN C, WELLHAM LL: Effect of MDR1 phosphorothioate antisense oligodeoxynucleotides in multi-drug-resistant human tumor cell lines and xenografts. Anti-Cancer Res. (2003) 23:2681–2690.
- •Demonstrates that the use of antisense-RNA against P-gp gives rise to a restoration of drug sensitivity. tantitumor agents (MDR). Curr. Med. Chem. (2002) 9:159–193.
- TEODORI E, DEI S, SCAPECCHI S, GUALTIERI F: The medicinal chemistry of multi -drug resistance (MDR)-reversing drugs . Farmaco (2002) 57:385–415.
- WIESE M, PAJEVA I: Structure–activity relationships of multi-drug resistance reversers. Curr . Med. Chem. (2001) 8:685–713.
- AVANDANO C, MENENDEZ JC: Inhibitors of multi-drug resistance to antitumor agents (MDR). Curr. Med. Chem . (2002) 9:159–193.
- KLOPMAN G, SHI LM, RAMU A: Quantitative structure-activity relationship of multi-drug resistance reversal agents. Mot Pharmacol. (1997) 52:323–334.
- ••A study presenting pharmacophoric andpharmacophobic substructures for inhibitors of P-gp on the basis of the analysis of 600 structurally diverse compounds.
- SEELIG A: A general pattern for substrate recognition by P-glycoprotein. Ear. J. Biochem. (1998) 251:252–261.
- •On the basis of a set of structurally diverse P-gp inhibitors, the distances of H-bond acceptor groups necessary for high biological activity are described.
- EKINS S, KIM RB, LEAKE BF et al: Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol . Pharmacol. (2002) 61:974–981.
- •Chemical function based pharmacophoric feature modeling is used to identify 3D-pharmacophore models for substrates and inhibitors of P-gp.
- PAJEVA I, WIESE M: Pharmacophore model of drugs involved in P-glycoprotein it multi-drug resistance: explanation of structural variety (hypothesis). .1: Med. Chem. (2002) 45:5671–5686.
- REBITZER S, ANNIBALI D, KOPP S et al.: hi silico screening with benzofurane-and benzopyrane-type MDR-modulators. Farmer° (2003) 58:185–191.
- •Several methods are presented using in silico screening of large compound libraries to identify new inhibitors of P-gp.
- CHAN LM, LOWES S, HIRST BH: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Ear. J. Pharm. Sci (2004) 21:25–51.
- •A recent review highlighting the role of drug efflux pumps for ADME.
- MINDERMAN H, BROOKS TA, O'LOUGHLIN KL, OJIMA I, BERNACKI RJ, BAER MR: Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives orataxel (IDN-5109, BAY-8862) and tRA96023. Cancer Chemother. Pharmacol (2004) 53:Jan 27 [Epub ahead of print].
- •Paper introducing the concept of broad spectrum ABC-transporter inhibitors.
- GARRAWAY LA, CHABNER B: MDR1 inhibition: less resistance or less relevance? Ear. J. Cancer (2002) 38:2337–2340.
- ••Excellent overview on the current situationof clinical trials.
- RENAU TE, LEGER R, FILONOVA L et al.: Conformationally restricted analogues of efflux pump inhibitors that potentiate the activity of levofloxacin in Pseudomonas aeruginosa. Bioorg. Med. Chem. Lett. (2003) 13:2755–2758.
- ••Presentation of compounds which inhibitbacterial efflux pumps.